SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr^® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the appointment of Vincent Wong, JD, MBA, to its board of directors.

Mr. Wong is currently the chief commercial officer at Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health. He joined Geneoscopy in March 2021 after almost 18 years at Roche Diagnostics, where he held senior leadership roles across the spectrum of commercial execution, including product marketing, sales, strategy, business development, market access and communications. His teams served physician groups, hospital systems, patients, biopharma, retail pharmacies and payors in the areas of diabetes, oncology, infectious disease and women's health.

“We are thrilled to have Vince joining the board of directors,” said Erik Holmlin, PhD, president and chief executive officer at Bionano Genomics. “Vince brings a depth of experience in commercial leadership, the pharmaceutical industry as well as market access and clinical diagnostics commercialization that complements the outstanding experience we already have across the board. I’m excited to work closely with Vince as we ramp up our commercial execution and advance efforts connected to market access for OGM.”

“I am excited about joining Erik and his colleagues on the board of directors at Bionano and going deeper into the genomics industry.” Vince added, “a significant portion of my time at Roche Diagnostics was in the Ventana business, which transformed anatomic pathology by automating outdated and cumbersome workflows through instrumentation and consumables, creating modernized workflows that delivered enhanced testing efficiency and medical value for labs, clinicians and patients. I believe Bionano can achieve something similar through its efforts to consolidate workflows in cytogenomics. I also believe the combination of OGM and next-generation sequencing data can enable the development of targeted therapeutics and is something the pharmaceutical industry could potentially leverage.”

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com.